Disc Medicine To Discuss FDA Updates On Bitopertin For Erythropoietic Protoporphyria (EPP)

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development, and commercialization of new treatment therapies for patients diagnosed with severe hematologic diseases. The company will hold a conference call to present the updates from the company’s Type C meeting on bitopertin for Erythropoietic Protoporphyria (EPP) with the FDA. The conference call will be held on Tuesday, January 21, at 8:00 am EST.